Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation

J Clin Microbiol. 2005 Oct;43(10):5395-6. doi: 10.1128/JCM.43.10.5395-5396.2005.

Abstract

We report a case of breakthrough invasive zygomycosis in a stem cell transplant recipient who was receiving caspofungin for treatment of a breakthrough Candida krusei fungemia that occurred during fluconazole prophylaxis. Also, patients receiving the echinocandin caspofungin remain at risk for pathogens, such as zygomycetes, that are intrinsically resistant to this agent.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Anemia, Aplastic / therapy
  • Antifungal Agents / therapeutic use*
  • Candida / classification
  • Candida / drug effects
  • Candidiasis / drug therapy
  • Candidiasis / microbiology*
  • Candidiasis / prevention & control
  • Caspofungin
  • Chemoprevention
  • Echinocandins
  • Fatal Outcome
  • Female
  • Fluconazole / therapeutic use*
  • Fungemia / drug therapy
  • Fungemia / microbiology*
  • Fungemia / prevention & control
  • Fungi
  • Humans
  • Lipopeptides
  • Peptides, Cyclic / therapeutic use*
  • Stem Cell Transplantation / adverse effects*
  • Zygomycosis / drug therapy
  • Zygomycosis / microbiology*
  • Zygomycosis / prevention & control

Substances

  • Antifungal Agents
  • Echinocandins
  • Lipopeptides
  • Peptides, Cyclic
  • Fluconazole
  • Caspofungin